Indaptus Therapeutics, Inc. has entered into a Stock Purchase Agreement with certain non-U.S. accredited investors for a private placement of its common stock. The agreement, dated June 17, 2026, is expected to generate approximately $12 million in gross proceeds for the company, intended for working capital, clinical development, and general corporate purposes.
Key Details
- Transaction Terms: The company agreed to issue and sell 20,000,000 shares of its common stock at a purchase price of $0.60 per share, resulting in gross proceeds of approximately $12,000,000.
- Agreement Date: The Stock Purchase Agreement was executed and closed on June 17, 2026.
- Registration Rights: The purchasers have been granted registration rights, requiring the company to file a registration statement with the SEC covering the resale of the shares within 90 days following the closing.